Pricing
PBMs, drugmakers face off over copay accumulators
April 19, 2018As with most drug pricing battles, patients yet again are caught in the crossfire.
High-profile candidates challenge marketers well in advance of launch
April 04, 2018With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
Five things for pharma marketers to know: Thursday, March 29, 2018
March 29, 2018PhRMA has released a series of new ads that blame high drug prices on cost increases to insurers and PBMs; Veterans Affairs Secretary Dr. David Shulkin has been fired; UK biotech Redx has suspended a Phase I/II trial of its cancer drug
Will PBMs take heat for high drug prices?
March 29, 2018PBMs began by providing a huge service to payers, but in recent years, they've begun to suck revenue from pharma manufacturers. Will they take some heat for high drug prices?
ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.
March 23, 2018In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?
Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?
March 13, 2018As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.
Azar's tough assignment: 'Rocketing down' drug prices
February 21, 2018The new HHS secretary has been given a difficult task by President Trump: bring drug prices down.
PhRMA takes Let's Talk About Cost campaign to the public
February 08, 2018PhRMA wants to clear the air about drug pricing with the consumer-focused extension of the Let's Talk About Cost campaign.
Five things for pharma marketers to know: Wednesday, January 31, 2018
January 31, 2018CDC chief resigns; Amazon healthcare entry raises data concerns; Trump promises to make lower drug prices 'a priority'
We Save Lives While Our Critics Complain
January 25, 2018In his first press conference as president-elect, Donald Trump insisted pharma was "getting away with murder" due to expensive drug prices.
Five things for pharma marketers to know: Tuesday, January 23, 2018
January 23, 2018FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Five things for pharma marketers to know: Friday, January 12, 2018
January 12, 2018Pharma looks to Spark for pricing blueprint; Ipsen hires Amgen exec as CEO of North America; FDA could improve social-media approach, study finds
Five things for pharma marketers to know: Thursday, January 11, 2018
January 11, 2018Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Taxpayers Need to Cough up the Cash to Keep Federal Agencies Afloat
January 08, 2018As we continue to debate the proper size and role of government in society, cast your eyes on recent polls by Gallup and Pew that found the majority of Americans felt their income tax was fair.
Five things for pharma marketers to know: Wednesday, January 3, 2018
January 03, 2018Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark's genetic therapy for rare blindness costs $850,000
Five things for pharma marketers to know: Tuesday, December 19, 2017
December 19, 2017Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets
MM&M 2018 staff predictions: From gift bans to Google Assistant
December 19, 2017From gift bans to Google Assistant, POC to OPDP, MM&M staff members give their predictions on what to expect in healthcare marketing in 2018
Five things for pharma marketers to know: Thursday, December 14, 2017
December 14, 2017Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business
Tax Bill Is Good News for Life Sciences and Marketing
December 11, 2017Although it's a long way from the president's desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.
Five things for pharma marketers to know: Tuesday, December 5, 2017
December 05, 2017Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds
Five things for pharma marketers to know: Friday, December 1, 2017
December 01, 2017FDA approves first Apple Watch health accessory; medical charity shared data with pharma donors; FDA approves opioid-addiction treatment
Five things for pharma marketers to know: Wednesday, November 8, 2017
November 08, 2017FDA to change Risk Evaluation Mitigation Strategies to prevent delayed generic approvals; Ohio rejects drug-price measure; Aetna CEO wants to improve in-person pharmacy experience
Five things for pharma marketers to know: Wednesday, November 1, 2017
November 01, 2017Drug industry spends nearly $50 million to fight drug-price referendum; Novartis weighs sales of generic unit; ICER to evaluate all newly approved drugs
Five things for pharma marketers to know: Thursday, October 26, 2017
October 26, 2017Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
Five things for pharma marketers to know: Wednesday, October 25, 2017
October 25, 2017FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs
10 questions for PhRMA's CEO Stephen Ubl
October 24, 2017Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.
Five things for pharma marketers to know: Wednesday, September 27, 2017
September 27, 2017AbbVie adds context to CEO's comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico
Five things for pharma marketers to know: Tuesday, September 26, 2017
September 26, 2017Patient assistance nonprofit contacted in Aegerion probe; most heavily marketed drugs in Canada offer little therapeutic value; the FDA pans Duchenne drug
Five things for pharma marketers to know: Wednesday, September 13, 2017
September 13, 2017FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts
Snubbing Intolerance: Frazier's Path Was Disengagement
September 01, 2017Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
